<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunohistochemical determination of p63 protein is frequently used in the pathologic diagnosis of nonhematological <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e>, p63 expression has been reported in 22% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, about 35% of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 23% of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, and in some cases of <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> that accounts for less than 5% of <z:hpo ids='HP_0000001'>all</z:hpo> cases of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>There is little information concerning p63 expression in this specific type of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In some cases, the morphological and phenotypic features between anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and classical Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are similar, making this differential diagnosis challenging </plain></SENT>
<SENT sid="5" pm="."><plain>We studied p63 expression using a tissue microarray approach in 154 cases of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, including 38% anaplastic large cell kinase positive and 62% anaplastic large cell kinase negative, and 58 Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases </plain></SENT>
<SENT sid="6" pm="."><plain>Sixty-eight cases of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (44%) showed p63 nuclear positivity (41% of anaplastic large cell kinase positive and 47% of anaplastic large cell kinase negative) </plain></SENT>
<SENT sid="7" pm="."><plain>Of 130 cases of systemic-anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 42% showed p63 positivity </plain></SENT>
<SENT sid="8" pm="."><plain>The neoplastic cells expressed p63 in 38% of the cases of CD45-negative/anaplastic large cell kinase-negative null cell-type anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, a subgroup that offers the most difficulties in the differential diagnosis with classical Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, none of the cases of classical Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> demonstrated any p63 expression </plain></SENT>
<SENT sid="10" pm="."><plain>These results demonstrate that p63 protein expression is frequently expressed in a subset of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases and may be used as a potential tool in the differential diagnosis between anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and classical Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>